2050908-30-8 Usage
Chemical structure
The compound consists of a pyrimidine ring with a chloro group at the 2-position, a fluoro group at the 5-position, and a methyl group at the 3-position, attached to a benzo[d]imidazole ring.
Pharmaceutical research
It is commonly used in pharmaceutical research due to its potential biological activity.
Antiviral and antitumor properties
The compound has potential as an antiviral or antitumor agent.
Biological targets
It has the potential for interacting with various biological targets.
Lead compound
It can serve as a lead compound for the development of new drugs.
Complex structure
The compound has a complex structure.
Pharmacological activities
It has potential pharmacological activities.
Further studies
Its complex structure and potential pharmacological activities make it a target for further chemical and biological studies.
Check Digit Verification of cas no
The CAS Registry Mumber 2050908-30-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,0,5,0,9,0 and 8 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 2050908-30:
(9*2)+(8*0)+(7*5)+(6*0)+(5*9)+(4*0)+(3*8)+(2*3)+(1*0)=128
128 % 10 = 8
So 2050908-30-8 is a valid CAS Registry Number.
2050908-30-8Relevant articles and documents
2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF
-
, (2018/07/29)
Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.
